Business Description
ATAI Life Sciences NV
ISIN : NL0015000DX5
Compare
Compare
Traded in other countries / regions
ATAI.USA9VC.GermanyATAI.Mexico IPO Date
2021-06-18Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.5 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.36 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.6 | |||||
Beneish M-Score | 1.98 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.6 | |||||
3-Year EPS without NRI Growth Rate | 14.9 | |||||
3-Year FCF Growth Rate | -57.7 | |||||
3-Year Book Growth Rate | 34.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 318.4 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.09 | |||||
9-Day RSI | 48.57 | |||||
14-Day RSI | 46.37 | |||||
6-1 Month Momentum % | -14.21 | |||||
12-1 Month Momentum % | -1.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.68 | |||||
Quick Ratio | 6.68 | |||||
Cash Ratio | 5.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -1.42 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -28353.97 | |||||
Net Margin % | -15363.23 | |||||
FCF Margin % | -20957.14 | |||||
ROE % | -26.11 | |||||
ROA % | -21.67 | |||||
ROIC % | -112.8 | |||||
ROC (Joel Greenblatt) % | -2499.31 | |||||
ROCE % | -21.79 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 655 | |||||
PB Ratio | 1.31 | |||||
Price-to-Tangible-Book | 1.31 | |||||
EV-to-EBIT | -2.77 | |||||
EV-to-Forward-EBIT | -0.91 | |||||
EV-to-EBITDA | -2.79 | |||||
EV-to-Forward-EBITDA | -1.39 | |||||
EV-to-Revenue | 399.74 | |||||
EV-to-Forward-Revenue | 167.89 | |||||
EV-to-FCF | -1.91 | |||||
Price-to-Net-Current-Asset-Value | 3.12 | |||||
Price-to-Net-Cash | 5.46 | |||||
Earnings Yield (Greenblatt) % | -36.1 | |||||
FCF Yield % | -36.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATAI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ATAI Life Sciences NV Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.378 | ||
EPS (TTM) ($) | -0.39 | ||
Beta | 0.79 | ||
Volatility % | 67.62 | ||
14-Day RSI | 46.37 | ||
14-Day ATR ($) | 0.093212 | ||
20-Day SMA ($) | 1.3355 | ||
12-1 Month Momentum % | -1.88 | ||
52-Week Range ($) | 1.025 - 2.85 | ||
Shares Outstanding (Mil) | 167.8 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ATAI Life Sciences NV Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
ATAI Life Sciences NV Frequently Asked Questions
What is ATAI Life Sciences NV(ATAI)'s stock price today?
The current price of ATAI is $1.31. The 52 week high of ATAI is $2.85 and 52 week low is $1.02.
When is next earnings date of ATAI Life Sciences NV(ATAI)?
The next earnings date of ATAI Life Sciences NV(ATAI) is 2024-11-14 Est..
Does ATAI Life Sciences NV(ATAI) pay dividends? If so, how much?
ATAI Life Sciences NV(ATAI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |